THCJD: banned in France since 2024 without being named
THCJD, or tetrahydrocannabioctyl, is a variant of THC with an eight-carbon side chain where THC has five. No published measurement shows it forming in meaningful amounts in hemp, so products sold under this name are synthetic. French law does not name it, yet its structure falls within the family of derivatives that the ANSM classified as narcotics from 3 June 2024.
Key takeaways
- THCJD shares the skeleton of THC but carries an 8-carbon side chain (formula C₂₄H₃₆O₂).
- Labels and certificates may call it THC-C8 or THC-octyl.
- Any substance derived from the benzo[c]chromene core and carrying an alkyl chain falls under the ANSM decision of 22 May 2024, THCJD included.
- Five US products sold as "THC-JD" were analysed in 2026, and none of them contained it.
- Its toxicity has never been assessed in humans.
What is THCJD?
THCJD is a homologue of Δ⁹-THC, the psychoactive molecule in cannabis. "Homologue" means the skeleton stays the same and only one chain changes length. The chain in question is attached at position 3: five carbons in THC, eight in THCJD. A 2026 study calls it a semi-synthetic cannabinoid with an eight-carbon side chain.
A certificate of analysis may list it as THC-C8, THC-octyl or 3-octyl-THC. "THC-O" is something else: THC acetate, a separate synthetic molecule. The letters "JD" belong to no chemical nomenclature.
The length of this chain affects how active the molecule is. The Italian team that isolated THCP in 2019 notes that synthetic THC analogues with a longer side chain have shown far higher cannabimimetic activity than THC itself. The seven-carbon homologue is described on our page on THCP.
Natural or synthetic?
In practice, synthetic. The 2026 study says THCJD exists only in trace amounts in hemp without citing any measurement, and we found no publication quantifying it in a plant. THCP differs on this point: it was isolated in 2019 from a medical cannabis variety and then confirmed by synthesis.
THCJD on the market is therefore made in a lab, often from other cannabinoids. A 2024 toxicology study describes the mechanism: the surplus of hemp-derived CBD can serve as raw material for the semi-synthesis of a whole range of THC variants. HHC came by the same route, as our timeline of the HHC ban shows.
What is known about its effects: almost nothing
No human trial exists, and the only solid pharmacological data come from cells. The 2024 study cited above tested 30 THC variants on the CB1 receptor, through which THC acts on the brain. THC-C8 was one of the homologues with a higher potential to activate CB1 than Δ⁹-THC. A cell test tells you nothing about dose, duration or toxicity in humans.
The "19 times stronger than THC" figure found online has no study behind it. The 2026 team traces it to a US cannabis trade association and does not endorse it.
For molecules in the same family, the ANSM's classification rests on reports received by France's addiction-monitoring centres. The agency lists vomiting, loss of consciousness, coma and seizures, and effects "more severe and more intense" than those of cannabis.
What "THC-JD" products actually contain
A name on the package guarantees nothing. In 2026, chemists at Portland State University analysed five vape products bought in the United States and sold as containing THC-JD, and found it in none of them. Four had Δ⁸-THC as their main compound, and the fifth contained THC acetate.
The molecule does circulate, however. A study of US online retail sites recorded THC-JD in 2023 among 26 different psychoactive compounds in 804 products examined, and more than half of those products (54%) blended two to eight of these compounds. A Japanese team also identified its two isomers in products sold online in Japan in 2022 and 2023.
Legal status in France: covered by a family definition
The ANSM has stopped classifying molecules only one at a time. Its decision of 22 May 2024, in force since 3 June 2024, adds "any substance derived from the benzo[c]chromene core" to the narcotics list, along with a list of permitted substitutions. At position 3, the text allows "an alkyl chain" among others, with no limit on length. With an octyl chain at that position, THCJD falls within this definition.
The exclusions are set out in a second decision of 3 June 2024: CBN and CBNA, THCV and THCVA below 0.3%, and THCA within the limit set by the order of 30 December 2021. THCJD is not one of these exceptions, so its absence from the named list gives no permission.
| Molecule | Side chain | Origin | Status in France |
|---|---|---|---|
| THCV | 3 carbons | Natural | Excluded from the list if content is 0.3% or less |
| Δ⁹-THC | 5 carbons | Natural | Narcotic, tolerated below 0.30% in authorised hemp |
| THCP | 7 carbons | Natural, isolated in 2019 | Narcotic since 3 June 2024 |
| THCJD | 8 carbons | Synthetic | Narcotic since 3 June 2024, via the family definition |
CBD rules stay the same: a CBD product is legal as long as it contains no more than 0.30% Δ⁹-THC, as our article on the permitted THC level explains.
How to avoid it
Watch for three warning signs. The first is wording built on effects, such as "stronger than THC", "new legal molecule" or "high"; a compliant CBD product is never sold on psychoactive effects. The second is a certificate listing THC-JD, THC-C8, THC-octyl or any acronym you do not recognise. The third is a missing certificate, or one without a batch number.
A lab finds only what it looks for. If the method did not search for THCJD, a certificate that omits it proves nothing about its absence. Where to look is shown in our guide to reading a certificate of analysis, and the other molecules to watch for in our article on synthetic cannabinoids in CBD. Our laboratory page lists the catalogue products.
Frequently asked questions
It is a variant of THC with an eight-carbon side chain, where THC has five. It is also sold as THC-C8, THC-octyl or tetrahydrocannabioctyl, and products containing it are synthetic.
Yes. Although it is not named, its structure places it in the family of benzo[c]chromene derivatives that the ANSM classified as narcotics, a classification in force since 3 June 2024. It is not among the exclusions.
None of the publications we reviewed has quantified it in a plant. Its seven-carbon neighbour, THCP, was isolated from a medical cannabis variety in 2019.
In a cell test published in 2024, it showed a higher potential than THC to activate the CB1 receptor. No study is behind the "19 times stronger" figure, and no human trial has been published.
Only an analysis that searches for the molecule can tell. Be wary of products sold on psychoactive effects, and of certificates that lack a batch number or list unfamiliar acronyms.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.